Frontage Holdings Corp. · HKEX:1521

Frontage — Frontage Laboratories — Investor Presentation (March 2010)

55 slides from Frontage's investor presentation, Mar 30, 2010

  1. Slide 1: Company Introduction

    Slide 1: Company Introduction

    aea@aBAA——— FRONTAGE moving your compound forward Company Introduction

  2. Slide 2: The Frontage Advantage

    Slide 2: The Frontage Advantage

    THE FRONTAGE ADVANTAGE Attention, Efficiency, and Expertise

  3. Slide 3: Who is Frontage Laboratories?

    Slide 3: Who is Frontage Laboratories?

    Who is Frontage Laboratories? • We are an early phase drug development company • Started in 2002 • Currently 225 people • We have grown organically and through acquisition (clinical) • selected as one of the fastest growing companies in the Philadelphia region – 4 years in a row • Facilities in US a

  4. Slide 4: Advantage #1 – Expediting your development program

    Slide 4: Advantage #1 – Expediting your development program

    Working with Frontage: Advantage #1 – Expediting your development program ACCOMPLISH MORE WITH ONE SERVICE SUPPLIER Frontage has all that you need to move your compound from preclinical development through Phase I – II clinical studies and beyond • API synthesis • Preclinical / ADME Services • Dosag

  5. Slide 5: Advantage #2 - 100% Attention

    Slide 5: Advantage #2 - 100% Attention

    Working with Frontage: Advantage #2 - 100% Attention WHAT SETS FRONTAGE APART?? Every project is on the front burner – 100% attention Communications are easy to manage, coordinated, and routinely scheduled Our project management leaders each have a minimum 15 years experience in the industry – You r

  6. Slide 6: Advantage #3 – Top Scientific Team

    Slide 6: Advantage #3 – Top Scientific Team

    Working with Frontage: Advantage #3 – Top Scientific Team YOUR DRUG DEVELOPMENT PROGRAM REQUIRES THE BEST TALENT Frontage has a significant number of advanced-degree scientists – >60% of our team Extensive personal experiences in all phases of drug development – from discovery to clinical, from labo

  7. Slide 7: Advantage #4 – Frontage US–China Operation

    Slide 7: Advantage #4 – Frontage US–China Operation

    Working with Frontage: Advantage #4 – Frontage US –China Operation QUALITY Globally managed, centralized data (all sites WATSON LIMS) Globally managed Quality System SCIENCE Frontage has the best training system in the industry • Management team has international experience • Scientists receive inte

  8. Slide 8: Frontage - Background

    Slide 8: Frontage - Background

    FRONTAGE - BACKGROUND Service Offerings

  9. Slide 9: Our Locations

    Slide 9: Our Locations

    Our Locations Hackensack, NJ (NYC area) Phase I-II Clinical Operations (72 beds) – expanding to 160 beds in 2010 Princeton, NJ CRO support services Malvern, PA Bioanalytical and Bioassay services, ADME (near Philadelphia) services GMP API manufacturing Exton, PA Corporate Headquarters (near Philadel

  10. Slide 10: Our Clients

    Slide 10: Our Clients

    Our Clients More than 200 clients around the world: US, EU, JP, China Global top 10, mid-size and virtual pharmaceutical and biotech firms Chinese generic and innovative drug companies Frontage has had successful FDA inspections (10+) and numerous client inspections and audits for both our US and Ch

  11. Slide 11: DMPK Preclinical Services Overview

    Slide 11: DMPK Preclinical Services Overview

    DMPK Preclinical Services Overview WORLD-RENOWNED LEADERSHIP Accomplished team of professionals Thought leaders in drug metabolism - over 100 years of collective experience in DMPK and ADME support and published research DMPK SERVICES Support for discovery pharmacokinetic studies Discovery-stage in-

  12. Slide 12: Discovery DMPK Services: PK Studies

    Slide 12: Discovery DMPK Services: PK Studies

    Discovery DMPK Services: PK Studies Exploratory Discovery Pre-Selection Lead Candidates DT PK in Pharmacology Model(s) Help with POC, MED exposure In-Life and Non-GLP Bioanalytical n PK/PD Biomarker n PK in Non-Rodent n Renal/Biliary Assessment Clearance n Target Tissue (As Needed) n PK in Other Exp

  13. Slide 13: Discovery DMPK Services: In-Vitro DMPK Studies

    Slide 13: Discovery DMPK Services: In-Vitro DMPK Studies

    Discovery DMPK Services: In-Vitro DMPK Studies Exploratory Discovery Pre-Selection Lead candidates DT • Metabolite Profiling/ Structure Elucidation - metabolic soft spots • Cross-species metabolism • Metabolism in human - structure optimization (microsomes/hepatocytes) plateable hepatocytes • Metabo

  14. Slide 14: Drug Development Phase DMPK: Metabolite Studies

    Slide 14: Drug Development Phase DMPK: Metabolite Studies

    Drug Development Phase DMPK: Metabolite Studies Phase 2 to Phase 0 Phase 1 Post-NDA IND SAD & MAD POC NDA n In vitro metabolism - [14C] n Metabolite profiles from n Human [14C] ADME study compound SAD/MAD studies n Metabolism support of n Single dose 14C metabolism n Determination of exposure of cli

  15. Slide 15: Discovery ADME Studies

    Slide 15: Discovery ADME Studies

    Discovery ADME Studies Metabolic stability (2 time points) – microsomes / hepatocytes Intrinsic clearance – microsomes / hepatocytes In-vitro metabolite identification for structural optimization Cross-species metabolite profiles across species – microsomes / hepatocytes CYP-450 inhibition – LC/MS/M

  16. Slide 16: Discovery ADME Studies (continued)

    Slide 16: Discovery ADME Studies (continued)

    Discovery ADME Studies Plasma metabolite profiling Plasma/blood partitioning studies Isolation and characterization of metabolites In-Life PK studies (in-life conduct through partners – internal small mammal capabilities available June 2010) CACO-2 / MDCK permeability studies (available July 2010) Q

  17. Slide 17: Development DMPK Studies

    Slide 17: Development DMPK Studies

    Development DMPK Studies Reaction phenotyping (cDNA & chemical inhibition) Metabolite profiling and identification – Tox/FIH studies Isolation and characterization of metabolites Delineation of metabolic pathways CYP inhibition studies. Definitive IC50 & k1 determinations (April 2010) CYP induction

  18. Slide 18: Development ADME Studies

    Slide 18: Development ADME Studies

    Development ADME Studies Synthesis of metabolites and stable-labeled materials The Frontage team has specific expertise for development of Metabolites In Safety Testing (MIST) packages. Identification of metabolites Quantitation of metabolites AUC determinations (using non-radiolabeled compounds) Ma

  19. Slide 19: DMPK Leadership Team

    Slide 19: DMPK Leadership Team

    DMPK Leadership Team • Abdul Mutlib: Twenty years of experience in pharmaceutical industry, (PhD) DuPont-Merck, Pfizer, Hoechst-Roussel (Aventis), Wyeth Five years post-doc in academia, 60+ publications, patents Editoral Board: Chemical Research in Toxicology • Jack Wang: • Jim Burleigh: Experienced

  20. Slide 20: DMPK Leadership Team

    Slide 20: DMPK Leadership Team

    DMPK Leadership Team Team Member Background Description Abdul Mutlieb (PhD) Twenty years of experience in pharmaceutical industry, DuPont-Merck, Pfizer, Hoechst-Roussel (Aventis), Wyeth Five years post-doc in academia, 60+ publications, patents, Editoral Board: Chemical Research in Toxicology Jack W

  21. Slide 21: DMPK Leadership Team continued

    Slide 21: DMPK Leadership Team continued

    DMPK Leadership Team continued: Team Member Background Description Li Shen (PhD) More than 10 years of experience in Development Drug Metabolism. Experience in mass balance studies, metabolite profiling, enzyme ID and kinetics, drug-drug interaction, enyme induction and inhibition. Expert in DM stud

  22. Slide 22: Bioanalytical Services

    Slide 22: Bioanalytical Services

    Bioanalytical Services INDUSTRY - LEADING TECHNICAL CAPABILITIES Highest ratio of advanced degreed scientists working on the bench From data management and sample handling to analysis platforms, Frontage has invested in state-of-art technology, including global Watson LIMS system Streamlined method

  23. Slide 23: Bioanalytical Services LC/MS/MS

    Slide 23: Bioanalytical Services LC/MS/MS

    Bioanalytical Services LC / MS / MS

  24. Slide 24: Bioanalytical Services

    Slide 24: Bioanalytical Services

    Bioanalytical Services GC & LC/MS/MS METHOD DEVELOPMENT & VALIDATION Demonstrated success in developing methods for compounds requiring high sensitivity measurements (picogram / mL) Small and large molecule analysis One of the most proficient labs in US and China – tackling technically challenging p

  25. Slide 25: State-of-Art Equipment and Processes

    Slide 25: State-of-Art Equipment and Processes

    State-of-Art Equipment and Processes 17 LC/MS/MS systems in USA (10 API 4000, 3 API 5000, 3 4000 API Q-trap, API365), 6 LC/MS/MS in China (4 API 4000, 1 API 5000, 1 API 4000 Q-trap) More than 30 HPLC systems 3 MSD Electro-chemilluminescence Instruments Watson LIMS system – centralized data for US an

  26. Slide 26: High Throughput Sample Preparation

    Slide 26: High Throughput Sample Preparation

    State-of-Art Equipment and Processes High Throughput Sample Preparation

  27. Slide 27: Electrochemiluminescence – Large Molecule Analysis

    Slide 27: Electrochemiluminescence – Large Molecule Analysis

    State-of-Art Equipment and Processes Electrochemiluminescence – Large Molecule Analysis

  28. Slide 28: Covaris Ultrasonic Extractor – Tissue Processing

    Slide 28: Covaris Ultrasonic Extractor – Tissue Processing

    State-of-Art Equipment and Processes Covaris Ultrasonic Extractor – Tissue Processing

  29. Slide 29: Exton CMC Facilities

    Slide 29: Exton CMC Facilities

    Exton CMC Facilities • Analytical Labs– 8,000 Sq Ft o GMP Analytical Instrumentation o ICH Stability Storage • Formulation Development & GMP Area ( 10,000 Sq Ft) o Solids R&D o Liquids / Creams / Ointments R&D o Potent Compounds suite (GMP) o Solids Dosage Manufacturing (GMP) o Liquids / Creams / Oi

  30. Slide 30: CMC Services - Analytical

    Slide 30: CMC Services - Analytical

    CMC Services - Analytical GMP & GLP ANALYTICAL SERVICES Method Development, Validations and Transfers • HPLC (25 systems), UPLC, GC, LC/MS/MS, GC/MS ICH Stability Evaluations – over 4,500 cubic feet of storage • Standard and Custom Conditions Dissolution Testing • Comparator Study Capability with On

  31. Slide 31: Analytical Equipment

    Slide 31: Analytical Equipment

    Analytical Equipment • 25 HPLC Systems – UV/PDA, CAD, Refractive Index, Fluorescence o Three vendor platforms for ease of method transfer / robustness (Waters, Agilent, Shimadzu) • UPLC Systems – PDA and MS • 3 GC Systems – FID with Headspace • Ion Chromatography (Dionex) • LC/MS/MS and GC/MS - Impu

  32. Slide 32: CMC Services - Stability

    Slide 32: CMC Services - Stability

    CMC Services - Stability • Stability Chambers Are Fully Compliant With ICH Guidelines • 7 Walk-in Stability Chambers And 5 Reach-ins With Over 4,500 Total Cubic Feet • Smaller Chambers And Photo stability Chamber For Special Studies • Lab Watch Monitoring System • Emergency Back-up Power Generator f

  33. Slide 33: CMC Services - Formulations

    Slide 33: CMC Services - Formulations

    CMC Services - Formulations FORMULATION DEVELOPMENT Rational Development Processes (CTD / QBR formats) Pre-formulation characterization and screening • Physicochemical evaluations • Excipient compatibility Immediate and Controlled Release Development Expertise • Oral Solid Dosage Forms – Immediate a

  34. Slide 34: Clinical Manufacturing

    Slide 34: Clinical Manufacturing

    Clinical Manufacturing • Phase I –II Scale • Full Range of Capabilities o Oral Solids -High Shear, Encapsulation, Compression, Tablet Coating, Fluid Bed o Sterile manufacturing utilizing disposable bag system o Semi Solids o Liquids capabilities to 100 L o High Potency Suites

  35. Slide 35: CMC Services

    Slide 35: CMC Services

    CMC Services GMP CONTRACT MANUFACTURING – CLINICAL TRIAL MATERIALS Oral Solid Dosage Forms • API filling in Capsules – Accurate Dosing System • Standard Tablet and Capsule filling • Tablet in Tablet technology (Tri-layer Tablet Press) • Liquid – filled Capsules • Enteric Coating Sterile Dosage Forms

  36. Slide 36: CMC Services: API Synthesis and Research Chemistry

    Slide 36: CMC Services: API Synthesis and Research Chemistry

    CMC Services API SYNTHESIS AND RESEARCH CHEMISTRY GMP Synthesis of Small Molecules – up to 5 kg scale Reference Standard Synthesis – Metabolite Synthesis & Cold Labeling – Impurity Identification and Purification Projects – Process Development & Optimization – Sourcing & Scale-up to Commercial

  37. Slide 37: Collaborations

    Slide 37: Collaborations

    Collaborations • BEIJING PHARMACEUTICALS GROUP – Large Scale, FDA-inspected GMP manufacturing • PIERRE FABRE (FRANCE) – Patented Nanotechnologies for enhancing bioavailability of low permeability / low solubility drugs – Taste masking of bitter API’s • HERAEUS (GERMANY) – Cytotoxic API Manufacturing

  38. Slide 38: Biomarkers & Biologics

    Slide 38: Biomarkers & Biologics

    FRONTAGE moving your compound forward Biomarkers & Biologics Frontage Laboratories will provide a full range of technology platforms, flexibility and customization to meet all your Biomarker and Biological Analytical requirements across various stages of preclinical & clinical development ¢ Our coll

  39. Slide 39: Biomarker and Biologics

    Slide 39: Biomarker and Biologics

    FRONTAGE . . . moving your compound forward Biomarker and Biologics

  40. Slide 40: Immunoanalytical Testing (Ligand-Binding Assays)

    Slide 40: Immunoanalytical Testing (Ligand-Binding Assays)

    Immunoanalytical Testing (Ligand-Binding Assays)

  41. Slide 41: Specialized Assays & Services

    Slide 41: Specialized Assays & Services

    Specialized Assays & Services

  42. Slide 42: Biologics: Assays & Services

    Slide 42: Biologics: Assays & Services

    Biologics: Assays & Services

  43. Slide 43: Biologics: Assays & Services

    Slide 43: Biologics: Assays & Services

    Biologics: Assays & Services CELL-BASED ASSAYS (PRE-CLINICAL AND CLINICAL) • Potency assay • Cytotoxicity and Proliferation assays • Immune function assays • Flowmetric assays • Tissue processing/staining for IHC • Custom assay development for client needs USA AND CHINA • Frontage provides these ser

  44. Slide 44: US Clinical Research Center: Background

    Slide 44: US Clinical Research Center: Background

    US Clinical Research Center: Background • Founded in 1994 – 16 year track record of service excellence • 72-bed unit located in Hackensack, New Jersey • On-site, full-time principal investigator with 20 years of emergency medicine experience • Phase 1 and 2a studies • On-site pharmacy (temperature c

  45. Slide 45: Clinical Research Centers: Phase 1 and 2 Studies

    Slide 45: Clinical Research Centers: Phase 1 and 2 Studies

    Clinical Research Centers: Phase 1 and 2 Studies • PHASE 1 AND 2A STUDY EXPERIENCE  First-in-human  Pharmacokinetics  Single dose escalation / repeated dose  Absolute and relative bioavailability  Bioequivalence studies (pilot, pivotal, fed, fasted)  Drug-drug interaction (DDI), drug-alcohol a

  46. Slide 46: Clinical Research Centers: Subject Recruitment

    Slide 46: Clinical Research Centers: Subject Recruitment

    Clinical Research Centers: Subject Recruitment • Proactive recruitment planning & execution • Extensive volunteer database (5000+ subjects) • Wide-ranging media options – newspapers and local publications, employment guides, local flyers and postings, radio • Local networking – schools, businesses,

  47. Slide 47: Clinical Research Centers: Proof-of-Concept Studies

    Slide 47: Clinical Research Centers: Proof-of-Concept Studies

    Clinical Research Centers: Proof-of Concept Studies – Proof of concept studies • Cardiovascular – endothelial dysfunction, HTN, early CV disease (Endo-PAT vascular compliance devices) • Metabolic – Type 1 and 2 DM, obesity, metabolic syndrome, dyslipidemias (dietician, on-site Hologic Dexascanner) •

  48. Slide 48: Clinical Research Centers: Study Time Lines

    Slide 48: Clinical Research Centers: Study Time Lines

    Clinical Research Centers: Study Time Lines • Rapid IRB submission process (Central IRB) – Study-specific approval typically within 8 business days of submission – Able to begin screening immediately with IRB-approved generic ICF • Dosing within 3 weeks of contract execution • Same-day shipment of p

  49. Slide 49: Clinical Research Centers: Study Metrics

    Slide 49: Clinical Research Centers: Study Metrics

    Clinical Research Centers: Study Metrics Since 2006, we have performed: • Over 25 bioequivalence studies (pilot and pivotal) – 2-way and 3-way cross-over – Fed and Fasted – Over 700 healthy male/female volunteers enrolled – Enrollment rate >98% – Completion rate >90% • Over 25 Phase 1 studies – Over

  50. Slide 50: Clinical Services Moving Forward

    Slide 50: Clinical Services Moving Forward

    Clinical Services Moving Forward • New US clinic to be constructed • 160-bed state-of-the-art Phase 1 clinic • Northern New Jersey location • Access to public transportation and diverse subject population • Ability to run 3 separate 24/36 subject panels simultaneously • Separate area with hospital b

  51. Slide 51: CRO Support Services

    Slide 51: CRO Support Services

    CRO Support Services • Full-service CRO for Phase 1-3 studies • Headquarters in Princeton, NJ • Experienced Senior Management Team • Protocol Design, ICF and CRF Development • Project Management • Clinical Data Management (Oracle Clinical) • SAS Programming • Biostatistical & Pharmacokinetic (WinNon

  52. Slide 52: China Clinical Research Center

    Slide 52: China Clinical Research Center

    China Clinical Research Center • Dedicated 130 bed unit located in Zhengzhou, China • Fit-Out completed in Q2 2009 • Supported by the First Affiliated Hospital of Zhengzhou University (4,000 bed hospital) • ICH GCP compliance • SOPs strictly follow Frontage’s U.S. practices

  53. Slide 53: Clinical Pharmacology & Regulatory Affairs

    Slide 53: Clinical Pharmacology & Regulatory Affairs

    Clinical Pharmacology & Regulatory Affairs • CLINICAL PHARMACOLOGY CONSULTATION • CONSULTATION ON DRUG DEVELOPMENT & REGISTRATIONS – Clinical Pharmacology – CMC – Toxicology – Regulatory Project Management • REGULATORY FILINGS (IND, NDA, & ANDA) • FDA COMMUNICATIONS – Agent representation – FDA Meet

  54. Slide 54: Get the Attention You Deserve

    Slide 54: Get the Attention You Deserve

    Get the Attention You Deserve • OUR ORGANIZATION HAS BEEN BUILT WITH YOU IN MIND! – Project management and program managers have proven industry experience – Key leaders of each business unit have proven track records in the industry – We are sufficiently staffed in each area to manage individual se

  55. Slide 55: Discussion & Next Steps

    Slide 55: Discussion & Next Steps

    we put your compound FRONT & CENTER DISCUSSION & NEXT STEPS

Source: Internet Archive copy of frontagelab.com

More decks from Frontage Holdings Corp.

All 11 Frontage decks